Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

Enhance patient outcomes by discussing treatment options for food allergy
Refine diagnostic skills for diagnosing penicillin allergy.
Implement safeguards for preventing food-induced anaphylaxis

Suggested Additional Reading & Joint Accreditation Statement - Note: This Accreditation Statement Supersedes All Other Statements:

Suggested Additional Reading:

Wood, RA, Togias, A, Sicherer, SH, et al. 2024. Omalizumab for the treatment of multiple food allergies. New England Journal of Medicine, 390(10), pp.889-899.
Casale, TB, Fiocchi, A. and Greenhawt, M., 2024. A practical guide for implementing omalizumab therapy for food allergy. Journal of Allergy and Clinical Immunology.
Copaescu, AM, Vogrin, S, James, F, et al., 2023. Efficacy of a clinical decision rule to enable direct oral challenge in patients with low-risk penicillin allergy: the PALACE randomized clinical trial. JAMA internal medicine, 183(9), pp.944-952.

Joint Accreditation Statement

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)

The University of Pittsburgh School of Medicine designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credits™.Each physician should only claim credit commensurate with the extent of their participation in the activity.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

Authors:

Andrej Petrov, MD — Associate Professor of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh School of Medicine
Dr. Petrov discloses he is a consultant with Genentech, Blueprint Medicines, CSL Behring, and Eli Lilly, and a stock holder of a publically traded company DBV Technologies.

Merritt Fajt, MD — Assistant Professor of Medicine, Division of Pulmonary Allergy, Critical Care, and Sleep Medicine. University of Pittsburgh School of Medicine
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Sara Van Meerbeke, MD — Clinical Instructor of Medicine, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Pittsburgh School of Medicine
No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity is approved for AMA PRA Category 1 Credit™

The University of Pittsburgh is an affirmative action, equal opportunity institution.